BioDelivery Sciences International (NASDAQ: BDSI)

BioDelivery Sciences is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.

The development strategy focuses on utilization of the FDA’s 505(b)(2) approval process to potentially obtain timely and efficient approval of new formulations of previously approved therapeutics which incorporate the company's licensed drug delivery technologies.

Read more about

BREAKING: 7/16 - FDA Approves BioDelivery's Painkiller ONSOLIS

For more information on BioDelivery and Onsolis, please download the documents below:

 

 

BEMA Fact Sheet Bioral Fact Sheet
Breakthough Pain Fact Sheet Commercial Partners Fact Sheet
ONSOLIS Fact Sheet Corporate Fact Sheet

 

BDSI held a webcast to discuss the approval of ONSOLIS on Friday, July 17, 2009, at 10:00 a.m. EST.  You can listen to the webcast below.

 

 

Market Data

In the News

Contact & RSS

Contacts

PR: Laura Colontrelle

212.825.3210                                                                                      

  

Subscribe to BioDelivery Sciences news, video, feature feeds, and more via RSS.

 

FriendFeed